INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 439m ago
HOUSE PTR39m ago
SEC 13F39m ago
ROBINHOOD CHAIN38m ago
SEC FORM 4/Grant or awardVerified data

Schimmelpennink Evert B. reported CTNM

Director · Contineum Therapeutics, Inc. · Contineum Therapeutics, Inc. — Stock Option (right to buy)

Side
A
Value
—
Shares
19.0K
Price
—
Executed
Jun 26, 2026
Disclosed
Jun 26, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Jun 26 executedJun 26, 2026 disclosed

CTNM · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · CTNM

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    LL
    Lyons-Williams LoriDirector
    CTNMContineum Therapeutics, Inc.
    Grant or award
    		A—
    19.0K sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    9
    MD
    Miralles Gines DiegoDirector
    CTNMContineum Therapeutics, Inc.
    Grant or award
    		A—
    19.0K sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    9
    IA
    Ignelzi Troy A.Director
    CTNMContineum Therapeutics, Inc.
    Grant or award
    		A—
    19.0K sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    9
    BR
    Brady Todd R.Director
    CTNMContineum Therapeutics, Inc.
    Grant or award
    		A—
    19.0K sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    9
    BS
    Boyce SarahDirector
    CTNMContineum Therapeutics, Inc.
    Grant or award
    		A—
    19.0K sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    9
    WC
    Ware Olivia CDirector
    CTNMContineum Therapeutics, Inc.
    Grant or award
    		A—
    19.0K sh
    		Jun 26, 2026Jun 26, 2026
    traded Jun 26, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001628280-26-045839
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 26, 2026
    Published
    Jun 26, 2026
    Ingested by INSIDER
    Nov 5, 03:50 UTC
    Last re-read
    Nov 5, 03:50 UTC

    Extracted facts

    Filer
    Schimmelpennink Evert B.
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Contineum Therapeutics, Inc. — Stock Option (right to buy)
    Ticker
    CTNM
    Shares
    19.0K
    Price per share
    $0
    Execution date (reported)
    Jun 26, 2026
    Owned after transaction
    19.0K shares
    Days from execution to publication
    0

    What this establishes

    Schimmelpennink Evert B. filed this Form 4 reporting a grant or award of CTNM on Jun 26, 2026. It became public on Jun 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Schimmelpennink Evert B.cik:0001713795
    Issuer
    Contineum Therapeutics, Inc.cik:0001855175

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.